# A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer

> **NCT04571489** · PHASE2 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gimatecan
- **DRUG:** tegafur, gimeracil and oteracil potassium
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT04571489
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571489, "A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04571489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*